Compounded Tirzepatide Dosage Guide & Chart
Compounded tirzepatide provides a cost-effective alternative to brand Mounjaro and Zepbound pens, with savings of 60-75%. Understanding the complete titration schedule, vial concentrations, and volume conversions ensures safe, accurate dosing for this powerful dual GLP-1/GIP receptor agonist.
Understanding Tirzepatide and Its Advantages Over Semaglutide
Tirzepatide is a dual GLP-1/GIP receptor agonist—it activates two separate appetite-regulating pathways in the brain, unlike semaglutide which activates only GLP-1 receptors. This dual mechanism produces superior weight loss compared to semaglutide: approximately 22% body weight reduction at maintenance dose versus 15-18% for semaglutide.
Tirzepatide is approved for both diabetes treatment (Mounjaro) and weight loss treatment (Zepbound). The titration schedule and dosing are identical for both indications. The higher potency of tirzepatide compared to semaglutide results in more pronounced appetite suppression, better glucose control, and more significant weight loss at equivalent treatment durations.
However, tirzepatide causes more intense gastrointestinal side effects than semaglutide, particularly nausea and vomiting. The longer titration schedule (6 steps over 20+ weeks versus 5 steps over 12+ weeks for semaglutide) allows gradual adjustment to minimize these effects.
Compounded tirzepatide is prepared from pharmaceutical-grade tirzepatide powder mixed with sterile solutions by licensed pharmacy compounders. The tirzepatide molecule is identical to brand Mounjaro and Zepbound, but the preparation and delivery system differ.
Complete Tirzepatide Titration Schedule
The FDA-approved tirzepatide titration schedule spans 6 steps over approximately 20 weeks, allowing gradual dose escalation to minimize gastrointestinal side effects.
Week 1-4: 2.5mg once weekly as the starting dose for all patients. Most patients tolerate 2.5mg tirzepatide with minimal side effects. This foundational dose initiates GLP-1/GIP receptor activation.
Week 5-8: 5mg once weekly. This doubles the initial dose and intensifies appetite suppression. Nausea may emerge or worsen at this dose level.
Week 9-12: 7.5mg once weekly. This intermediate dose further increases weight loss efficacy. Many patients experience peak nausea at this transition.
Week 13-16: 10mg once weekly. This dose produces substantial weight loss for most patients. Some patients achieve desired results here and remain on 10mg long-term.
Week 17-20: 12.5mg once weekly. Higher-dose patients progress here. Weight loss continues to increase at this dose.
Week 21+: 15mg once weekly as the maximum approved maintenance dose. This is the highest dose used in clinical trials. Most studies achieved maximal weight loss results at 15mg. Some patients remain on lower doses if earlier doses produce adequate results.
The standard interval between dose increases is 4 weeks, allowing body adaptation. However, some patients titrate faster (every 2-3 weeks) or slower (every 6-8 weeks) based on side effect tolerance. Discuss your titration pace with your prescribing provider.
Tirzepatide Dosage Chart and Concentration Conversions
The following chart shows the complete tirzepatide dosing schedule with calculated volumes for standard compounded concentrations:
| Week | Dose (mg) | Volume @ 5mg/mL | Volume @ 10mg/mL | Volume @ 20mg/mL | Frequency |
|---|---|---|---|---|---|
| 1-4 | 2.5 | 0.5 mL | 0.25 mL | 0.125 mL | Once weekly |
| 5-8 | 5.0 | 1.0 mL | 0.5 mL | 0.25 mL | Once weekly |
| 9-12 | 7.5 | 1.5 mL | 0.75 mL | 0.375 mL | Once weekly |
| 13-16 | 10.0 | 2.0 mL | 1.0 mL | 0.5 mL | Once weekly |
| 17-20 | 12.5 | 2.5 mL | 1.25 mL | 0.625 mL | Once weekly |
| 21+ | 15.0 | 3.0 mL | 1.5 mL | 0.75 mL | Once weekly |
Calculating Injection Volume for Your Tirzepatide Concentration
To determine the correct injection volume for any dose and concentration, use this simple formula:
Volume (mL) = Desired Dose (mg) / Vial Concentration (mg/mL)
Example: If you need a 7.5mg dose and your vial is labeled 5mg/mL, the volume = 7.5mg / 5mg/mL = 1.5mL. You would draw 1.5mL from the vial into your insulin syringe and inject.
Converting to syringe units: Standard insulin syringes measure in units (100 units = 1mL). One unit = 0.01mL. Therefore: 0.5mL = 5 units. 1.0mL = 10 units. 1.5mL = 15 units. 2.0mL = 20 units. 2.5mL = 25 units. 3.0mL = 30 units.
For a 5mg/mL concentration, the dose/units conversion is straightforward: 2.5mg = 5 units. 5mg = 10 units. 7.5mg = 15 units. 10mg = 20 units. 12.5mg = 25 units. 15mg = 30 units.
For a 10mg/mL concentration: 2.5mg = 2.5 units. 5mg = 5 units. 7.5mg = 7.5 units. 10mg = 10 units. 12.5mg = 12.5 units. 15mg = 15 units.
For a 20mg/mL concentration: 2.5mg = 1.25 units. 5mg = 2.5 units. 7.5mg = 3.75 units. 10mg = 5 units. 12.5mg = 6.25 units. 15mg = 7.5 units.
Choosing the Optimal Tirzepatide Concentration
Three tirzepatide concentrations are commonly available from compounding pharmacies: 5mg/mL, 10mg/mL, and 20mg/mL. Each offers different practical advantages and challenges.
5mg/mL concentration is most practical for patients undergoing the full titration schedule. Starting dose (2.5mg) requires 0.5mL—easily measurable. Maintenance dose (15mg) requires 3mL—within standard syringe capacity. All intermediate doses produce measurable volumes between 0.5mL and 3mL. This concentration minimizes measurement errors and is recommended for most patients.
10mg/mL concentration produces smaller volumes, which some patients prefer for psychological reasons. However, starting dose (2.5mg) requires 0.25mL—half a standard unit on insulin syringes. Maintenance dose (15mg) requires 1.5mL—easily measurable. The challenge is precise measurement of very small starting doses.
20mg/mL concentration produces the smallest volumes but is impractical for titration. Starting dose (2.5mg) requires 0.125mL—one-eighth of a standard unit on insulin syringes. Measuring this accurately is nearly impossible with standard insulin syringes. This concentration is appropriate only for patients already at maintenance doses who can reliably measure smaller volumes or have access to tuberculin syringes marked in 0.01mL increments.
Recommendation: Choose 5mg/mL concentration for the full titration schedule. It provides accurate, measurable volumes throughout the entire treatment course without requiring specialized equipment.
Converting from Insulin Syringes to Tirzepatide Dosing Units
Standard insulin syringes are marked in units (U-100 syringes have 100 units = 1mL). Converting your tirzepatide dose to units ensures accurate measurement with standard equipment.
For 5mg/mL concentration, the conversion is simple: Each unit on the syringe equals 0.05mg tirzepatide. Therefore: 2.5mg = 5 units. 5mg = 10 units. 7.5mg = 15 units. 10mg = 20 units. 12.5mg = 25 units. 15mg = 30 units. These doses align perfectly with standard syringe markings.
For 10mg/mL concentration: Each unit equals 0.1mg tirzepatide. Therefore: 2.5mg = 2.5 units. 5mg = 5 units. 7.5mg = 7.5 units. 10mg = 10 units. 12.5mg = 12.5 units. 15mg = 15 units. You'll need to mark between standard unit lines for odd-numbered doses.
For 20mg/mL concentration: Each unit equals 0.2mg tirzepatide. This creates challenging measurements. 2.5mg = 1.25 units (between lines). 5mg = 2.5 units (between lines). Only doses that are multiples of 10mg (10mg = 5 units) fall exactly on standard syringe markings. This is why 20mg/mL is not recommended for titration.
Ask your compounding pharmacy for a printed unit conversion chart specific to your concentration. Mark your syringes with small pieces of tape at the correct fill line to aid consistent measurement.
Tirzepatide vs Semaglutide Dosing Comparison
While tirzepatide and semaglutide are both GLP-1 receptor agonists (tirzepatide is also a GIP agonist), they have dramatically different dosing schedules and potencies.
Semaglutide titrates in 5 steps over approximately 12 weeks: 0.25mg, 0.5mg, 1mg, 1.7mg, 2.4mg maximum. Tirzepatide titrates in 6 steps over approximately 20 weeks: 2.5mg, 5mg, 7.5mg, 10mg, 12.5mg, 15mg maximum.
Weight loss efficacy favors tirzepatide. At maximum doses, tirzepatide produces approximately 22% body weight loss versus 15-18% for semaglutide in clinical trials. The dual GIP mechanism amplifies weight loss.
Side effects are more pronounced with tirzepatide. Gastrointestinal effects, particularly nausea and vomiting, are more common and intense. The longer titration schedule partially mitigates this by allowing gradual adjustment.
Cost-wise, both are similar when compounded: semaglutide $200-400/month, tirzepatide $300-500/month. Brand medications show larger differences: Ozempic/Wegovy $1,200-1,500/month versus Mounjaro/Zepbound $1,300-1,600/month.
Proper Injection Technique for Tirzepatide
Tirzepatide is administered as a subcutaneous injection once weekly. Recommended injection sites include the abdomen (avoiding the area 2 inches around the navel), thigh, or upper arm.
Before drawing a dose, inspect the vial. The solution should be clear and colorless to slightly yellowish. Cloudiness, particles, or abnormal appearance indicates contamination; discard the vial.
Allow refrigerated vials to warm to room temperature for 10-15 minutes before injection. Cold injections are uncomfortable. Using a new, sterile insulin syringe each time, carefully draw your measured dose from the vial using sterile technique.
Cleanse the injection site with an alcohol wipe, allow it to dry (5-10 seconds), then pinch the skin to create a fold. Insert the needle at a 45-90 degree angle and depress the plunger slowly and steadily. After injection, apply gentle pressure for 10-15 seconds. Rotate injection sites to prevent lipohypertrophy (thickened fat deposits from repeated injections).
Never reuse needles or inject from contaminated syringes. Dispose of used needles in a sharps container. Each vial is for single-patient use only.
Storage, Stability, and Vial Management
Compounded tirzepatide must be refrigerated at 36-46°F (2-8°C). A standard kitchen refrigerator is appropriate. Label vials clearly with the date received and expiration date provided by the pharmacy.
Most compounded tirzepatide vials remain stable for 28 days after opening if properly refrigerated. Some formulations may differ; always check the label for specific expiration dates. After the expiration date, discard unused vials.
Never freeze tirzepatide. Freezing destroys the peptide molecule and renders it inactive. If a vial freezes accidentally, discard it immediately.
If a vial has been unrefrigerated, estimate the duration. Less than 1 hour: likely safe. 1-3 hours: questionable, consider discarding. More than 3 hours: discard. During travel, use insulated cases with ice packs to maintain proper temperature.
Draw and inject each dose immediately from the refrigerated vial. Do not pre-draw doses into syringes for later injection, as this degrades tirzepatide and increases contamination risk. Each injection requires fresh drawing from the vial.
Dose Adjustments and Titration Modifications
The standard 4-week intervals between dose increases can be modified based on individual tolerance. If side effects are severe at a dose level, remain at that dose for 6-8 weeks or longer before increasing, allowing better adjustment.
Some patients titrate faster (every 2-3 weeks) with good tolerance. Others slow their titration to minimize side effects. Discuss timing modifications with your healthcare provider.
Not all patients need to reach the 15mg maximum dose. Some achieve desired weight loss at 10mg or 12.5mg and maintain those doses long-term. If you achieve adequate results at a lower dose, discuss remaining there rather than continuing titration.
If you plateau on weight loss despite adequate doses, discuss with your provider. Options include remaining at current dose (weight loss sometimes resumes after months), increasing to the next dose level, or attempting lifestyle modifications. Switching to a different medication is rarely necessary if tirzepatide doses are adequate.
Comparison of Compounded vs Brand Tirzepatide
Compounded tirzepatide and brand Mounjaro/Zepbound contain identical tirzepatide molecules. Efficacy and side effects are identical at equal doses. The differences are practical and financial.
Brand Mounjaro and Zepbound are delivered via easy-to-use pre-filled pens with dose selectors. You dial your dose and inject with minimal effort. Compounded tirzepatide requires manual measurement into a syringe and self-injection, requiring more patient skill and responsibility.
Pricing differs dramatically. Brand medications cost $1,300-1,600 monthly; compounded costs $300-500 monthly—a 60-75% savings. For uninsured patients, this difference is decisive.
FDA approval differs. Mounjaro and Zepbound are FDA-approved finished products with extensive quality oversight. Compounded tirzepatide is state-regulated but lacks finished-product FDA approval. Quality depends on compounding pharmacy standards.
Convenience strongly favors brand pens. However, if cost is a primary concern and you're comfortable with injections and measurement, compounded tirzepatide offers identical medication at a fraction of the cost.
Related Guides & Resources
Frequently Asked Questions
The standard tirzepatide titration schedule is: Week 1-4: 2.5mg once weekly. Week 5-8: 5mg once weekly. Week 9-12: 7.5mg once weekly. Week 13-16: 10mg once weekly. Week 17-20: 12.5mg once weekly. Week 21+: 15mg once weekly as maintenance dose. This 6-step titration allows gradual dose escalation over 20-21 weeks, minimizing gastrointestinal side effects and allowing body adaptation at each dose level. Some patients achieve desired weight loss before reaching 15mg and remain on lower maintenance doses. Each dose is administered as a subcutaneous injection once weekly on the same day each week.
Three primary concentrations are available: 5mg/mL (5mg tirzepatide per 1mL) is the most common for lower doses. 10mg/mL (10mg per 1mL) offers moderate concentration for medium doses. 20mg/mL (20mg per 1mL) is highest concentration for maximum dose patients or those preferring very small volumes. The 5mg/mL concentration is most practical for titration schedules because dose volumes remain measurable throughout the titration progression. Higher concentrations (10mg/mL, 20mg/mL) may require very small volumes at starting doses, making accurate measurement challenging with standard insulin syringes.
Volume = Dose / Concentration. For 2.5mg dose: with 5mg/mL vial, volume = 2.5mg ÷ 5mg/mL = 0.5mL. With 10mg/mL vial, volume = 2.5mg ÷ 10mg/mL = 0.25mL. With 20mg/mL vial, volume = 2.5mg ÷ 20mg/mL = 0.125mL. For 15mg dose: with 5mg/mL vial, volume = 15mg ÷ 5mg/mL = 3mL. With 10mg/mL vial, volume = 15mg ÷ 10mg/mL = 1.5mL. With 20mg/mL vial, volume = 15mg ÷ 20mg/mL = 0.75mL. Lower concentrations produce larger volumes; higher concentrations produce smaller volumes. Create a conversion chart for your specific concentration before starting injection.
Compounded tirzepatide and brand Mounjaro contain identical tirzepatide molecules, so pharmacologic effects (weight loss, diabetes control, side effects) are identical at equal doses. Key differences: (1) Mounjaro comes in convenient pre-filled pens with dose selectors; compounded comes in vials requiring manual measurement. (2) Mounjaro is FDA-approved; compounded lacks finished-product FDA approval. (3) Mounjaro costs $1,300-1,600/month; compounded costs $300-500/month. (4) Mounjaro has extensive quality assurance; compounded depends on pharmacy standards. (5) Mounjaro is more convenient but significantly more expensive. Compounded tirzepatide offers 60-75% cost savings if you're comfortable with self-measurement and injection.
Mounjaro is tirzepatide approved for type 2 diabetes treatment. Zepbound is identical tirzepatide approved for weight loss treatment in patients without diabetes. The medication, dosing schedules, concentrations, and side effects are identical. The distinction is purely regulatory and insurance-related. Mounjaro is prescribed for diabetes management; Zepbound is prescribed for weight loss. Insurance coverage differs between the two brands even though they're the same medication. Compounded tirzepatide doesn't distinguish between Mounjaro and Zepbound formulations; it's simply tirzepatide prepared from bulk powder at specified concentrations.
Standard insulin syringes measure in units (100 units = 1mL) with 0.5-unit increments. This provides accuracy to about 0.005mL or 0.05mg tirzepatide. For most doses, this accuracy is adequate. However, starting doses (2.5mg to 5mg) from high-concentration vials (20mg/mL) may require volumes of 0.125-0.25mL, approaching the limit of syringe accuracy. For optimal accuracy with compounded tirzepatide, choose 5mg/mL or 10mg/mL concentrations. These produce measurable volumes throughout the entire titration schedule. If forced to use 20mg/mL concentration, ask your pharmacy for tuberculin (small volume) syringes marked in 0.01mL increments for improved precision.